THURSDAY, Feb. 17, 2022 (HealthDay News) — For patients with type 2 diabetes, current use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and SGLT2is combined with glucagon-like peptide 1 receptor agonists (GLP-1RAs) may be beneficial for prevention of major adverse cardiac and cerebrovascular events (MACCE), while SGLT2is, GLP-1RAs, and their combination may prevent heart failure, according to a study published online Jan. 31 in Diabetes Care.
Alison K. Wright, Ph.D., from the University of Manchester in the United Kingdom, and colleagues examined the associations between current use of SGLT2is, GLP-1RAs, and their combination and the risk for MACCE and heart failure in three nested case-control studies involving patients with type 2 diabetes. Each patient experiencing an event was matched with up to 20 controls.
The researchers found that 5.5 percent of the 336,334 people with type 2 diabetes and without cardiovascular disease experienced a MACCE, and 4.2 percent of 411,206 with type 2 diabetes and without heart failure experienced a heart failure event. The adjusted pooled odds ratio for MACCE was 0.82 (95 percent confidence interval [CI], 0.73 to 0.92), 0.93 (95 percent CI, 0.81 to 1.06), and 0.70 (95 percent CI, 0.50 to 0.98) for SGLT2i, GLP-1RA, and SGLT2i/GLP-1RA combination regimens, respectively, compared with other combination regimens. The corresponding odds ratios for heart failure were 0.49 (95 percent CI, 0.42 to 0.58), 0.82 (95 percent CI, 0.71 to 0.95), and 0.43 (95 percent CI, 0.28 to 0.64).
“Clinical trials of these agents and their combination are called for in the primary prevention setting to evaluate efficacy and cost-effectiveness,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
